Methods, Measures and Medications – Lessons from Schizophrenia

Chairs: Nina R. Schooler, PhD; Ilise Lombardo, MD

Cognitive impairment in schizophrenia (CIAS) has been a target for medication development for a number of years. Methods have been developed for assessment and a regulatory path has been outlined. A number of programs have been initiated, although no medications for this indication are available. The session will review the current status of CIAS with the goals of informing development for other disease areas and to examine future directions in methods development in CIAS. Following review of current status (Marder) there will be two presentations of CIAS programs designed to lead to regulatory approval that address trial designs, assessment measures and choice of pharmacologic targets (Haig and Lombardo). Future directions in assessment will be addressed by Green and Carter. Last, the question of how patients can be assessed in clinical settings for this indication will be considered based on an ISCTM consensus conference held in early 2014 (Keefe).